Ken Griffin’s Jyong Biotech MENS Stock Holding History

Ken Griffin’s Portfolio MENS Stock Details MENS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,641	Closed	-$498K	–	14637
2025 Q3	$498K	Sell	12,641 -58,329	-82%	-$2.1M	﹤0.01%	9154
2025 Q2	$591K	Buy	+70,970	New	+$609K	﹤0.01%	8247

Other funds holding MENS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Ken Griffin's MENS Position: Q4 2025 in Review

Ken Griffin sold out of Jyong Biotech (MENS) in Q4 2025, closing a stake of 12,641 shares — an estimated $498K sold.

Ken Griffin first reported a position in MENS in Q2 2025 and held it in 2 quarters. The position peaked at $591K in Q2 2025. 19 funds tracked by Wall St. Rank hold MENS as of Q4 2025.

Ken Griffin reported no remaining Jyong Biotech position as of Q4 2025 after selling out during the quarter.
Ken Griffin sold 12,641 Jyong Biotech shares in Q4 2025, an estimated $498K.
Ken Griffin first reported a position in Jyong Biotech in Q2 2025 and held it in 2 quarters.
Ken Griffin's Jyong Biotech position peaked at $591K in Q2 2025.
19 funds tracked by Wall St. Rank held Jyong Biotech as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.